Pure Global
NCT06404281

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Anti-PD-1 Antibody Armored γδ T Cells in the Treatment of Advanced Solid Tumors, a Phase I Clinical Trail
Changzhou No.2 People's Hospital·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
γδ T-PD-1 Ab cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Changzhou No.2 People's Hospital
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Jun 01, 2026
Enrollment
9 participants
Primary outcome

Safety evaluation: Incidence of Adverse events (AEs),Safety evaluation: Dose limited toxicity (DLTs),Safety evaluation: Maximum-tolerated dose (MTD)

Summary

This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to
 conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ
 T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06404281
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06404281 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou No.2 People's Hospital and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.